How Expanded Glioblastoma Trial Will Impact Alpha Tau Medical Stock (DRTS)
Alpha Vantage · Simply Wall Street · · AI-summarised by FinFlash
Alpha Tau Medical (DRTS) recently received FDA approval for an IDE supplement for its U.S. REGAIN trial in recurrent glioblastoma, expanding enrollment to 20 patients and broadening eligibility to include IDH-mutant grade 4 tumors. This expansion, along with new endpoints like progression-free survival and quality-of-life measures, aims to build a stronger clinical evidence base for its Alpha DaRT platform.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.